2025 ICD-10-CM code C92.6
Acute myeloid leukemia (AML) with 11q23-abnormality.
Medical necessity for diagnostic testing and treatment is established by the patient's clinical presentation, signs, and symptoms suggestive of AML, along with confirmatory laboratory and genetic test results indicating the 11q23 abnormality. The specific treatment approach chosen should be justified based on the patient's age, disease stage, and overall health status.
Diagnosis involves physical examination, blood tests (CBC, peripheral smear, blood chemistries, coagulation studies), bone marrow biopsy or aspiration, lumbar puncture for CSF analysis, microscopic and cytologic analysis of CSF, blood, and bone marrow, flow cytometry, PCR, FISH, genetic analysis, immunohistochemistry, and imaging studies (CT, MRI, PET, ultrasound). Treatment includes chemotherapy, targeted chemotherapy, stem cell transplant, radiation therapy, and surgery.
In simple words: AML with 11q23 abnormality is a type of blood cancer that mostly affects children. It happens because of a problem with a specific gene.
Acute myeloid leukemia (AML) with 11q23-abnormality is a type of AML characterized by a chromosomal abnormality of 11q23 involving the mixed lineage leukemia (MLL) gene. It is a recurring genetic abnormality and is more common in children.
Example 1: A 4-year-old child presents with easy bruising, fatigue, and bone pain. After diagnostic tests, including a bone marrow biopsy, the child is diagnosed with AML with 11q23-abnormality., A 6-year-old child with recurrent infections and persistent fever is found to have abnormal blood counts. Further genetic testing reveals a 11q23 abnormality, confirming the diagnosis of AML., An adult patient presents with symptoms similar to other AML subtypes. Genetic analysis shows the presence of the 11q23 abnormality, leading to a diagnosis of AML with 11q23-abnormality, which, while more common in children, can occur in adults.
Documentation should include patient history, physical exam findings (enlarged lymph nodes, bruising, bleeding), complete blood count (CBC) results, peripheral blood smear findings, blood chemistry profiles, coagulation studies, bone marrow biopsy or aspirate results, cytogenetic analysis demonstrating the 11q23 abnormality, and results of other diagnostic tests like FISH, PCR, flow cytometry. Treatment documentation should include the type of chemotherapy or targeted therapy administered, stem cell transplant details if performed, radiation therapy records, and surgical reports if applicable.
- Specialties:Hematology, Oncology, Pediatric Hematology-Oncology
- Place of Service:Inpatient Hospital, Outpatient Hospital, Physician's Office